MedPath

IMUGENE LIMITED

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

9

Active:1
Completed:1

Trial Phases

2 Phases

Phase 1:5
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (62.5%)
Phase 2
3 (37.5%)

A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)

Phase 1
Recruiting
Conditions
Solid Tumor, Adult
Interventions
Biological: CF33-CD19 IT Monotherapy
Biological: CF33-CD19 IV Monotherapy
Biological: CF33-CD19 IT Combination
Biological: CF33-CD19 IV Combination
First Posted Date
2023-10-02
Last Posted Date
2025-04-09
Lead Sponsor
Imugene Limited
Target Recruit Count
50
Registration Number
NCT06063317
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Emory Winship Cancer Institute, Atlanta, Georgia, United States

and more 5 locations

Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study

Recruiting
Conditions
Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study
First Posted Date
2023-04-20
Last Posted Date
2025-05-14
Lead Sponsor
Imugene Limited
Target Recruit Count
75
Registration Number
NCT05822427
Locations
🇺🇸

Science 37, Inc., Culver City, California, United States

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Solid Tumor
Solid Carcinoma
Solid Tumor, Adult
Cholangiocarcinoma
Bile Duct Cancer
Metastatic Cancer
Advanced Solid Tumor
Interventions
First Posted Date
2022-04-26
Last Posted Date
2025-06-15
Lead Sponsor
Imugene Limited
Target Recruit Count
100
Registration Number
NCT05346484
Locations
🇺🇸

University of Arizona Cancer Center, Tucson, Arizona, United States

🇺🇸

Highlands Oncology, Springdale, Arkansas, United States

🇺🇸

City of Hope Medical Center, Duarte, California, United States

and more 9 locations

A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)

Phase 2
Terminated
Conditions
Gastric Cancer
Stomach Adenocarcinoma
Stomach Cancer
Gastric Adenocarcinoma
Cancer of Stomach
Gastroesophageal Junction Adenocarcinoma
Interventions
First Posted Date
2022-04-05
Last Posted Date
2025-05-11
Lead Sponsor
Imugene Limited
Target Recruit Count
7
Registration Number
NCT05311176
Locations
🇦🇺

Southern Medical Day Care Centre, Wollongong, New South Wales, Australia

🇦🇺

The Queen Elizabeth Hospital, Woodville South, South Australia, Australia

🇨🇳

Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan

and more 4 locations

A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults with Non-Small Cell Lung Cancer

Phase 1
Active, not recruiting
Conditions
Non Small Cell Lung Cancer
Non Small Cell Lung Cancer Stage IIIB
Non-small Cell Lung Cancer Stage IV
Large Cell Carcinoma Lung
Squamous Non-small-cell Lung Cancer
Adenocarcinoma Lung
Interventions
Biological: IMU-201 (administered as PD1-Vaxx) - Regimen 1
Biological: IMU-201 (administered as PD1-Vaxx) - Regimen 2
Biological: IMU-201 (administered as PD1-Vaxx) - Regimen 3
Drug: Standard of care chemotherapy
First Posted Date
2020-06-16
Last Posted Date
2024-11-07
Lead Sponsor
Imugene Limited
Target Recruit Count
24
Registration Number
NCT04432207
Locations
🇺🇸

Mayo Clinic, Phoenix, Arizona, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

Ohio State University Medical Center, Columbus, Ohio, United States

and more 3 locations
  • Prev
  • 1
  • 2
  • Next

News

Imugene's Azer-cel Achieves 75% Response Rate in Phase 1b Trial for Relapsed DLBCL

Imugene's azer-cel, an allogeneic off-the-shelf CAR T therapy, demonstrated a 75% overall response rate with 55% complete response rate in patients with relapsed/refractory diffuse large B-cell lymphoma who had failed multiple prior therapies.

Imugene Secures AU$5.87 Million R&D Tax Refund to Advance Immuno-Oncology Pipeline

Imugene Limited received AU$5.87 million in R&D tax refunds from the Australian Government's incentive program, providing up to 48.5% refundable offset for eligible research activities.

HER-Vaxx Plus Chemotherapy Shows Survival Benefit in HER2-Overexpressing Gastric Cancer

• A phase II trial of HER-Vaxx plus chemotherapy demonstrated a 40% survival benefit compared to chemotherapy alone in patients with HER2-overexpressing gastric cancer. • The HER-Vaxx vaccine induced strong HER2-specific IgG and IgG1 antibody responses, correlating with tumor reduction and inhibition of intracellular phosphorylation. • The vaccine's mechanism of action includes antibody-dependent cellular cytotoxicity (ADCC) and counteraction of immune tolerance effects, enhancing chemotherapy's impact. • The study suggests HER-Vaxx is safe and immunogenic, warranting further evaluation in larger trials and combination therapies for advanced gastric cancer.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.